Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RD13-02 in r/r CD7+ NK/T Cell Malignancies
NCT06732492Phase 1Recruiting
- Start
- Oct 2024
- Primary completion
- Dec 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RD13-02 in Natural killer T-cell lymphoma (NKTL). Primary endpoints: Overall Response Rate at 4 weeks, Safety Evaluation and 1 more. Started Oct 2024; status: recruiting.
02
Drugs
RD13-02
03
Conditions
Natural killer T-cell lymphoma (NKTL)
Beyond the preview
Go deeper on NCT06732492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06732492.